结直肠癌肝转移综合治疗现状vdi0xzzh.pptVIP

* * * * * * 5-FU, 5-fluorouracil; DFS, disease-free survival; LV, leucovorin; R, randomization. The AURC 9002 study was a recent European trial that evaluated adjuvant therapy in patients with resectable liver metastases. Eligible patients were randomly assigned to receive either surgery alone or surgery followed by 6 cycles of 5?fluorouracil (5-FU) and leucovorin, using the Mayo Clinic approach. Of the 171 patients who enrolled in the trial, 95% had 3 or fewer liver metastases, indicating that these patients had lower risk disease. The primary outcome measure in this trial was disease-free survival (DFS). * DFS, disease-free survival. Results of this trial showed a statistically significant 7?month gain in median DFS among patients who received chemotherapy compared with those who received surgery alone (median DFS: 24.4 vs 17.6 months, respectively; P = .028). * * * * * * PFS:无进展生存期 * * * * CI, confidence interval; CT, computed tomography; EORTC, European Organization for Research and Treatment of Cancer; HR, hazard ratio; Periop, perioperative. Analysis of 3-year progression?free survival data from EORTC 40983 showed a 9.2% gain among patients in the perioperative arm compared with those in the surgery-only arm (42.4% vs 33.2%, respectively). This difference in progression-free survival reached statistical significance (P = .025), although the rate was lower than what had been anticipated according to the trial design. For more information about this trial, go online to: /Oncology/Conference%20Coverage/Clin%20Onc%20June%202007/Tracks/Gastrointestinal%20Cancer/Capsules/LBA5.aspx * * * CT, chemotherapy; EGFR, epidermal growth factor receptor; PD, progressive disease * * BRiTE, First-Line Bevacizumab Regimens: Investigation of Treatment Effects and Safety; BBP, bevacizumab beyond first progression; NE, not yet estimated; OS, overall survival * * 5-FU, 5-fluorouracil; CF, leucovorin calcium; DEX, dexamethasone; HAI, hepatic artery infusion; R, randomization. In the